1-iodomethyl-2-methyl-cyclohexane | 98551-93-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机碘化物
• 英文名称: 1-iodomethyl-2-methyl-cyclohexane
• 英文别名: 1-Jodmethyl-2-methyl-cyclohexan；1-(Iodomethyl)-2-methylcyclohexane
• CAS: 98551-93-0
• 化学式: C₈H₁₅I
• 分子量: 238.112
• InChiKey: RBEORXOZTXVETC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  2-甲基环己烷甲醇 在 三碘化磷 作用下， 生成 1-iodomethyl-2-methyl-cyclohexane
  参考文献：
  名称：

  Dunet et al., Bulletin de la Societe Chimique de France, 1956, p. 906,910

  摘要：

  DOI：

文献信息

• Monohalogenation of Zirconacyclopentane Complexes via Alkylalkoxyzirconocene
  作者：Tamotsu Takahashi、Koichiro Aoyagi、Ryuichiro Hara、Noriyuki Suzuki

  DOI：10.1246/cl.1992.1693

  日期：1992.9

  butene-butene coupling product on zirconium, with methanol followed by bromine gave selectively monobromination product, 2-ethyl-3-methyl-1-bromopentane, in 89% yield with high stereoselectivity. Similarly, non-conjugated diene cyclization products on zirconium were also selectively converted into monohalogenated compounds. These selective monohalogenations proceeded via alkylalkoxyzirconocene complexes

  用甲醇和溴处理反式-3,4-二乙基锆并环戊烷络合物（锆上的选择性丁烯-丁烯偶联产物）得到选择性单溴化产物 2-乙基-3-甲基-1-溴戊烷，产率为 89%高立体选择性。同样，锆上的非共轭二烯环化产物也被选择性地转化为单卤代化合物。这些选择性单卤化反应是通过烷基烷氧基锆茂配合物进行的。
• ACETYLCHOLINESTERASE INHIBITOR COMPOUNDS AND 5HT4 SEROTONERGIC RECEPTOR AGONISTS, WITH PROMNSIA EFFECT, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：UNIVERSITE DE CAEN

  公开号：US20160122300A1

  公开（公告）日：2016-05-05

  Compounds are provided according to Formula (I) as well as their enantiomers and their racemics, their acid salts, their hydrates or their solvation products. Among a large number of possible meanings, X represents a halogen, Y an oxygen atom; all of the coefficients m, n, r and s have the value 1, R represents an ethyl and R′ a cycloalkyl. The invention also includes Methods of preparing the above compounds and the pharmaceutical compositions containing them also are provided.

  化合物根据公式（I）提供，以及它们的对映体和它们的混合物，它们的酸盐，它们的水合物或它们的溶剂化物。在许多可能的含义中，X代表卤素，Y代表氧原子；所有系数m，n，r和s的值均为1，R代表乙基，R′代表环烷基。该发明还包括制备上述化合物的方法以及含有它们的制药组合物。
• ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE
  申请人：Samsung Electronics Co., Ltd.

  公开号：EP3943499A2

  公开（公告）日：2022-01-26

  An organometallic compound represented by Formula 1:          Formula 1     M(L1)n1(L2)n2 wherein M is a transition metal, L1 is a ligand represented by Formula 2 as provided herein, n1 is 1, 2, or 3, wherein, when n1 is 2, two L1 groups are identical to or different from each other, and when n1 is 3, two or more of three L1 groups are different from each other, L2 is a monodentate ligand, a bidentate ligand, a tridentate ligand, or a tetradentate ligand, and n2 is 0, 1, 2, 3, or 4, wherein, when n2 is 2 or greater, two or more L2 groups are identical to or different from each other, and L1 and L2 are different from each other.

  由式 1 表示的有机金属化合物： 式 1 M(L1)n1(L2)n2 其中 M 是过渡金属，L1 是由本文提供的式 2 所代表的配体，n1 是 1、2 或 3，其中当 n1 是 2 时，两个 L1 基团彼此相同或不同，当 n1 是 3 时，三个 L1 基团中的两个或更多彼此不同、L2 是单齿配体、双齿配体、三齿配体或四齿配体，且 n2 为 0、1、2、3 或 4，其中，当 n2 为 2 或更大时，两个或多个 L2 基团彼此相同或不同，且 L1 和 L2 彼此不同。
• COMPOSES INHIBITEURS DE L'ACETYLCHOLINESTERASE ET AGONISTES DES RECEPTEURS SEROTONINERGIQUES 5HT4, A EFFET PROMNESIANT, LEURS PROCEDES DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：Université de Caen

  公开号：EP3004058B1

  公开（公告）日：2020-06-10
• Annellated carbamyl-aza-heterocyclic compounds, a focused library, pharmaceutical compositions, and methods of preparing the same
  申请人：Ivashchenko Alexander

  公开号：US20070191337A1

  公开（公告）日：2007-08-16

  This invention relates to novel annellated carbamyl-aza-heterocyclic compounds that are potential physiologically active compounds (agonists, antagonists, and receptor modulators, enzyme inhibitors, oncolytics, antibacterial and antiparasitic agents, and so on), to a focused library comprising annellated carbamyl-aza-heterocyclic compounds, a pharmaceutical composition comprising annellated carbamyl-aza-heterocyclic compounds as the active ingredient, and to methods of producing and using the same. The invention relates to annellated carbamyl-aza-heterocyclic compounds of general formula 1: wherein: W is 6-oxopiperazine, [1,4]diazepan, [1,4]thiazepan or [1,4]oxazepan compound annellated to at least one optionally substituted and optionally condensed heterocyclic compound Q; R 1 , R 2 and R 3 are, independently of one another, a hydrogen atom, an inert substituent, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted phenyl, an optionally substituted aryl, or an optionally substituted heterocyclyl; and Q is a pyrrole, pyrazole, imidazole, thiazole, pyrrolidine, indole, benzofuran, 4,5,6,7-tetrahydrobenzothiophene, thieno[3,2-b]pyrrole, furo[3,2-b]pyrrole, thieno[2,3-b]pyrrole, benzimidazole, pyridine, quinoline, or 1,2,3,4-tetrahydroisoquinoline cyclic compound.